RBC Capital Downgrades Summit Materials to Sector Perform, Announces $37 Price Target
RBC Capital analyst Mike Dahl downgrades Summit Materials (NYSE:SUM) from Outperform to Sector Perform and announces $37 price target.
Morgan Stanley Maintains Equal-Weight on Summit Materials, Raises Price Target to $36
Morgan Stanley analyst Courtney Yakavonis maintains Summit Materials (NYSE:SUM) with a Equal-Weight and raises the price target from $35 to $36.
Return on Capital Employed Insights for Summit Materials
After pulling data from Benzinga Pro it seems like during Q2, Summit Materials (NYSE:SUM) earned $94.52 million, a 452.32% increase from the preceding quarter.
Unusual Options Activity Insight: Summit Materials
Summit Materials (NYSE:SUM) shares experienced unusual options activity on Tuesday. The stock price moved up to $35.2 following the option alert.
Morgan Stanley Maintains Equal-Weight on Summit Materials, Lowers Price Target to $35
Morgan Stanley maintains Summit Materials (NYSE:SUM) with a Equal-Weight and lowers the price target from $36 to $35.
RBC Capital Maintains Outperform on Summit Materials, Raises Price Target to $37
RBC Capital analyst Mike Dahl maintains Summit Materials (NYSE:SUM) with a Outperform and raises the price target from $36 to $37.
Summit Materials Q2 Adj. EPS $0.49 Misses $0.52 Estimate, Sales $618.53M Miss $642.05M Estimate
Summit Materials (NYSE:SUM) reported quarterly earnings of $0.49 per share which missed the analyst consensus estimate of $0.52 by 5.77 percent. This is a 2 percent decrease over earnings of $0.50 per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
